

DIVI'S LABORATORIES LIMITED

UNAUDITED FINANCIAL RESULTS (STANDALONE)
FOR THE QUARTER AND HALF YEAR ENDED 30TH SEPTEMBER, 2015

PART I

(₹. in Lakhs)

Sl No.	Particulars	STANDALONE					
		Unaudited					Audited
		Quarter ended			Half Year ended		Year Ended
	30.09.2015	30.06.2015	30.09.2014	30.09.2015	30.09.2014	31.03.2015	
	(1)	(2)	(3)	(4)	(5)	(6)	(7)
1	Income from operations						
	(a) Net Sales/Income from operations (Net of Excise Duty)	96187	80691	82977	176878	146953	307230
	(b) Other Operating Income	245	185	337	430	627	1171
	Total Income from operations (net)	96432	80876	83314	177308	147580	308401
2	Expenses						
	a. Cost of materials consumed	42106	35567	41097	77673	70769	144627
	b. Purchases of stock-in-trade		0	0		0	0
	c. Changes in inventories of finished goods, work-in-progress and stock-in-trade	(3571)	(3513)	(6040)	(7084)	(10818)	(23083)
	d. Employee benefits expense	8595	8033	6948	16628	12966	28315
	e. Depreciation and amortization expense	3007	2892	2926	5899	6252	13585
	f. Other Expenses	11702	10804	10629	22506	20466	42337
	Total Expenses	61839	53783	55560	115622	99635	205781
3	Profit from Operations before Other Income, Interest & Exceptional Items (1-2)	34593	27093	27754	61686	47945	102620
4	Other Income	2964	3399	1554	6363	2823	4284
5	Profit from ordinary activities before finance costs & exceptional Items (3+4)	37557	30492	29308	68049	50768	106904
6	Finance Costs	34	22	43	56	79	186
7	Profit from ordinary activities after finance costs but before exceptional Items (5-6)	37523	30470	29265	67993	50689	106718
8	Exceptional items	0	0	0	0	0	0
9	Profit from ordinary activities	37523	30470	29265	67993	50689	106718

	before Tax (7-8)						
10	Tax Expense	7950	6152	6301	14102	10932	22012
11	Net Profit from ordinary activities after Tax (9-10)	29573	24318	22964	53891	39757	84706
12	Extra-ordinary items (net of tax expense)	0	0	0	0	0	0
13	Net Profit (+)/Loss(-) for the period (11-12)	29573	24318	22964	53891	39757	84706
14	Share of profit / (loss) of associates	0	0	0	0	0	0
15	Minority Interest	0	0	0	0	0	0
16	Net Profit (+)/Loss(-) after taxes, minority interest and share of profit/ (loss) of associates (13+14+15)	29573	24318	22964	53891	39757	84706
17	Paid-up Equity Share Capital (Face Value : Rs.2 per share)	5309	2655	2655	5309	2655	2655
18	Reserves excluding revaluation reserves as per balance sheet of previous accounting year						353541
19.i	Earnings per Share (before extraordinary items) (of Rs.2/- each) (not annualized):						
	a) Basic	11.14	9.16	8.65	20.30	14.98	31.91
	b) Diluted	11.14	9.16	8.65	20.30	14.98	31.91
19.ii	Earnings per Share (after extraordinary items) (of Rs.2/- each) (not annualized):						
	a) Basic	11.14	9.16	8.65	20.30	14.98	31.91
	b) Diluted	11.14	9.16	8.65	20.30	14.98	31.91

PART II

A	PARTICULARS OF SHAREHOLDING						
1	Public shareholding - No. of shares - Percentage of shareholding	127207348 47.92%	63603674 47.92%	63603674 47.92%	127207348 47.92%	63603674 47.92%	63603674 47.92%
2	Promoters and promoter group shareholding a) pledged / encumbered b) non-encumbered: - No. of shares - Percentage of shares (as a % of the total shareholding of the promoter group) - Percentage of shares (as a % of the total share capital of the company)	Nil 138261232 100% 52.08%	Nil 69130616 100%	Nil 69130616 100%	Nil 138261232 100% 52.08%	Nil 69130616 100%	Nil 69130616 100%

	Particulars	Quarter ended 30-09-2015
B	INVESTOR COMPLAINTS	
	Pending at the beginning of the quarter	Nil
	Received during the quarter	9
	Disposed off during the quarter	9
	Remaining unresolved at the end of the quarter	Nil

Statement of Assets and Liabilities:

(₹. in lakhs)

	Particulars	STANDALONE As At	
		30.09.2015	31.03.2015
A	EQUITY AND LIABILITIES		
1	Shareholders' Funds		
	a) Share Capital	5309	2655
	b) Reserves and Surplus	404778	353541
	c) Money received against share warrants	0	0
	Sub-total – Shareholders' funds	410087	356196
2	Share application money pending allotment	0	0
3	Minority interest	0	0
4	Non-current liabilities		
	a) Long-term borrowings	105	105
	b) Deferred tax liabilities (net)	13934	13245
	c) Other long-term liabilities	0	0
	d) Long-term provisions	809	699
	Sub-total – Non-current liabilities	14848	14049
5	Current Liabilities		
	a) Short-term borrowings	3563	2507
	b) Trade payables	29008	22438
	c) Other current liabilities	16469	20273
	d) Short-term provisions	2153	32014
	Sub-total – Current liabilities	51193	77232
	TOTAL - EQUITY AND LIABILITIES	476128	447477
B	ASSETS		
1	Non-current assets		
	a) Fixed assets	159062	152690
	b) Goodwill on consolidation	0	0
	c) Non-current investments	282	282
	d) Deferred tax assets (net)	0	0
	e) Long-term loans and advances	15854	14907
	f) Other non-current assets	0	0
	Sub-total – Non-current assets	175198	167879
2	Current assets		

a) Current investments	65997	73300
b) Inventories	122131	111490
c) Trade receivables	98728	82303
d) Cash and bank balances	6245	5666
e) Short-term loans and advances	7171	5916
f) Other current assets	658	923
Sub-total – Current assets	300930	279598
TOTAL - ASSETS	476128	447477

NOTES:

1. The above results for the quarter ended 30th September 2015, as reviewed by the Audit Committee, were considered and approved by the Board of Directors at its meeting held on 31st October, 2015 and were subjected to 'limited review' by the Auditors.
2. The Company is primarily engaged in the manufacture of Active Pharmaceutical Ingredients and intermediates. Accordingly there are no reportable segments as per Accounting Standard 17 notified under the Companies Act, 1956.
3. As per Clause 41 of the listing agreement, the company has opted to publish quarterly unaudited standalone results and to publish consolidated results at the year end.
4. Details of forex gain/loss are given below:

	Quarter ended			Half Year ended		Year Ended
	30.09.2015	30.06.2015	30.09.2014	30.09.2015	30.09.2014	31.03.2015
Forex gain/(loss)	1166	2122	432	3288	567	(105)

Forex gain has been included in Other Income and forex loss has been included in Other Expenses.

5. Bonus Issue: During the current quarter, the company has allotted 13,27,34,290 bonus shares of Rs.2 each to the members on 28th September, 2015. The Earnings per Share has been adjusted for previous periods presented due to the bonus issue, in accordance with Accounting Standard No.20.
6. As approved by the Members of the company at the 25th Annual General Meeting on 31st August, 2015, the company has disbursed on 10th September, 2015 a dividend of ₹ 20 per equity share of Rs.2 each for the year ended 31st March, 2015, amounting to Rs. 26546.86 lakhs.
7. Figures for the previous year/period have been regrouped or recasted, wherever necessary.

for Divi's Laboratories Limited

Place: Hyderabad
Date: 31st October, 2015

Dr. Murali K. Divi
Chairman & Managing Director